Reacciones adversas a los fármacos antituberculosis en pacientes de 0 a 18 años atendidos en la unidad de tuberculosis del Hospital Infantil Doctor Robert Reid Cabral, junio - diciembre 2017. República Dominicana
Date
Subject
tuberculosis
child
drugs
treatment
adverse reactions
tuberculosis
infantil
farmacos
tratamiento
reacciones adversas
child
drugs
treatment
adverse reactions
tuberculosis
infantil
farmacos
tratamiento
reacciones adversas
Language:
Journal Title
Journal ISSN
Volume Title
Publisher
Intituto Tecnológico de Santo Domingo (INTEC)
Introducción: la Tuberculosis infantil representa del 6 al 10 % de los casos de TB, la OMS estimó para el 2017 unos 560 (rango: 380 – 740) casos en menores de 15 años en República Dominicana1. De los 122 casos diagnosticados en RD, 53 fueron en nuestro hospital. Los efectos adversos es una de las primeras causas de abandono de tratamiento en TB; los infantes no escapan a esta realidad.
Objetivo: determinar las reacciones adversas a los fármacos antituberculosis en pacientes (RAFA) de 0 a 18 años atendidos en la unidad de tuberculosis del Hospital Infantil Dr. Robert Reid Cabral, junio-diciembre 2017.
Metodología: estudio descriptivo y transversal, con recolección de datos retrospectiva. Revisamos todos los expedientes de la unidad de tuberculosis diagnosticados durante junio-diciembre 2017.
Resultados: de los 29 pacientes con tratamiento anti-TB, 16 (55.2 %) presentaron efectos adversos (RAFA), 62 % en la primera fase. El sexo más afectado fue el masculino (51.7 %). La mayor prevalencia en los grupos de 5-9 y 10-14 años con 27.6 %, respectivamente. El 62 % de los casos fueron de origen rural. La educación del padre fue desconocida en el 79 % de los casos y de la madre 37.9 %. El 89.7 % de los casos con efectos adversos recibieron drogas de primera línea, y el 10.3 % drogas de segunda línea. Los efectos gastrointestinales fueron los más frecuentes; las náuseas en el 17.2 %, seguida por los vómitos con un 10.3 % de primera línea. Mientras los que utilizaron segunda línea, la náusea se presentó en 6.9 % y los vómitos en 10.3 %. Dentro de los efectos adversos el 93.8 % se clasificaron como leve. El 37 % de los pacientes finalizaron sin complicaciones.
Conclusión: la medicación anti-tuberculosis es segura y los efectos adversos no afectaron la adherencia al tratamiento en el grupo estudiado.
Introduction: Childhood Tuberculosis represents 6 to 10 % of TB cases, WHO estimates about 750 cases in children under 15 in the Dominican Republic1. Of the 122 cases diagnosed in RD, 53 were in our hospital. Adverse effects is one of the first causes of treatment abandonment in TB, infants do not escape this reality. Objective: To determine the adverse reactions to antituberculosis drugs in patients (RAFA) from 0 to 18 years old treated in the tuberculosis unit of the Dr. Robert Reid Cabral Children's Hospital, June - December 2017. Methodology: Descriptive and transversal study, retrospective data collection. We reviewed all the records of the tuberculosis unit diagnosed during June-December 2017. Results: Of the 29 patients with anti-TB treatment, 16 (55.2 %) had adverse effects (RAFA), 62 % in the first phase. The sex most affected was male (51.7 %). The highest prevalence in the groups of 5-9 and 10-14 years with 27.6 % respectively. 62 % of the cases were of rural origin. The education of the father was unknown in 79 % and of the mother 37.9 %. 89.7 % of the cases with adverse effects received first line drugs, and 10.3 % second line drugs. The gastrointestinal effects were the most frequent; nausea in 17.2 %, followed by vomiting with 10.3 % of first line. While those who used the second line, nausea occurred in 6.9 % and vomiting in 10.3 %. Among the adverse effects, 93.8 % were classified as mild. 37 % of patients completed treatment successfully, 58 % are in the support phase without complications. Conclusion: The anti-tuberculosis medication is safe and the adverse effects did not affect the adherence to the treatment in the group studied.
Introduction: Childhood Tuberculosis represents 6 to 10 % of TB cases, WHO estimates about 750 cases in children under 15 in the Dominican Republic1. Of the 122 cases diagnosed in RD, 53 were in our hospital. Adverse effects is one of the first causes of treatment abandonment in TB, infants do not escape this reality. Objective: To determine the adverse reactions to antituberculosis drugs in patients (RAFA) from 0 to 18 years old treated in the tuberculosis unit of the Dr. Robert Reid Cabral Children's Hospital, June - December 2017. Methodology: Descriptive and transversal study, retrospective data collection. We reviewed all the records of the tuberculosis unit diagnosed during June-December 2017. Results: Of the 29 patients with anti-TB treatment, 16 (55.2 %) had adverse effects (RAFA), 62 % in the first phase. The sex most affected was male (51.7 %). The highest prevalence in the groups of 5-9 and 10-14 years with 27.6 % respectively. 62 % of the cases were of rural origin. The education of the father was unknown in 79 % and of the mother 37.9 %. 89.7 % of the cases with adverse effects received first line drugs, and 10.3 % second line drugs. The gastrointestinal effects were the most frequent; nausea in 17.2 %, followed by vomiting with 10.3 % of first line. While those who used the second line, nausea occurred in 6.9 % and vomiting in 10.3 %. Among the adverse effects, 93.8 % were classified as mild. 37 % of patients completed treatment successfully, 58 % are in the support phase without complications. Conclusion: The anti-tuberculosis medication is safe and the adverse effects did not affect the adherence to the treatment in the group studied.
Description
Type
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
info:eu-repo/semantics/publishedVersion
Source
Science and Health; Vol 3 No 2 (2019): Science and Health, may-August; 43-48
Ciencia y Salud; Vol. 3 Núm. 2 (2019): Ciencia y Salud, mayo-agosto; 43-48
2613-8824
2613-8816
10.22206/cysa.2019.v3i2
Ciencia y Salud; Vol. 3 Núm. 2 (2019): Ciencia y Salud, mayo-agosto; 43-48
2613-8824
2613-8816
10.22206/cysa.2019.v3i2